Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc., an emerging growth company incorporated in Delaware, on August 1, 2025. The report covers events occurring between July 23, 2025, and July 30, 2025.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a specific equity transaction.
Material Changes
- Unregistered Sales of Equity Securities: Between July 23, 2025, and July 30, 2025, the Company issued 243,429 shares of Common Stock.
- Source of Issuance: These shares were issued upon the conversion of approximately 564.76 shares of Series B Convertible Preferred Stock.
- Regulatory Basis: The issuance relied on the exemption from registration requirements under Section 4(a)(2) of the Securities Act.
- Capitalization Update: As of July 30, 2025, the total number of Common Stock shares outstanding was 3,139,861.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure of the unregistered stock issuance.
Investor Verification Checklist
- Verify the conversion ratio and terms of the Series B Convertible Preferred Stock.
- Confirm the updated total share count of 3,139,861 in subsequent filings.
- Review the Company's cash position to assess the impact of preferred stock conversions on future dilution.